Kuehn Law Encourages NARI, QTRX, CCRN, and VTS Investors to Contact Law Firm
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 24 2025
0mins
Source: Globenewswire
Investigation by Kuehn Law: Kuehn Law, PLLC is investigating potential shareholder claims regarding proposed mergers involving Inari Medical, Quanterix Corporation, Cross Country Healthcare, and Vitesse Energy to ensure shareholder value maximization and fair processes.
Shareholder Participation Encouraged: Shareholders are urged to get involved in the investigation as their participation is crucial for maintaining integrity in financial markets, with Kuehn Law covering all case costs.
Analyst Views on QTRX
Wall Street analysts forecast QTRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTRX is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
0 Buy
3 Hold
0 Sell
Hold
Current: 7.950
Low
5.00
Averages
6.00
High
7.00
Current: 7.950
Low
5.00
Averages
6.00
High
7.00
About QTRX
Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
